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Abstract
Background: The incidence of esophageal adenocarcinoma (EAC) has risen rapidly in the U.S. and western world. The aim of
the study was to begin the investigation of this rapid rise by developing, calibrating, and validating a mathematical disease
simulation model of EAC using available epidemiologic data.
Methods: The model represents the natural history of EAC, including the essential biologic health states from normal
mucosa to detected cancer. Progression rates between health states were estimated via calibration, which identified distinct
parameter sets producing model outputs that fit epidemiologic data; specifically, the prevalence of pre-cancerous lesions
and EAC cancer incidence from the published literature and Surveillance, Epidemiology, and End Results (SEER) data. As an
illustrative example of a clinical and policy application, the calibrated and validated model retrospectively analyzed the
potential benefit of an aspirin chemoprevention program.
Results: Model outcomes approximated calibration targets; results of the model’s fit and validation are presented.
Approximately 7,000 cases of EAC could have been prevented over a 30-year period if all white males started aspirin
chemoprevention at age 40 in 1965.
Conclusions: The model serves as the foundation for future analyses to determine a cost-effective screening and
management strategy to prevent EAC morbidity and mortality.
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Introduction
The vast majority of esophageal cancers are either squamous
cell carcinoma (SCC) or adenocarcinoma (EAC). Although
esophageal SCC incidence has been declining in the U.S. and
other parts of the western world, EAC incidence has experienced
an alarming, greater than five-fold, increase over the past three
decades [1]. This makes EAC the solid tumor with the most
rapidly increasing incidence. Although the absolute number of
EAC cases per year remains too low to screen the general
population [2], targeted screening of high risk individuals may be
appropriate. Heartburn, the primary symptom of gastroesopha-
geal reflux disease (GERD), affects 60 million Americans [3] and
can lead to Barrett’s esophagus (BE). BE is a pre-malignant
condition associated with the greatest risk (30–125 times) of
developing EAC [4]. The management of these patients has
become a significant public health issue because of the significant
number of individuals affected by GERD and BE. The
development of clinical and policy guidelines for disease
management requires evidence, such as results from clinical trials.
However, the relatively low rate of progression to cancer [5] has
made clinical trials with cancer endpoints challenging because of
the large number of subjects and long follow-up period required.
Additionally, no single clinical study can evaluate all the possible
screening and management strategies, both current and pending,
that attempt to diminish the morbidity caused by EAC. These
factors have presented obstacles in developing an acceptable
screening and surveillance strategy.
A lack of quality clinical data from controlled studies of
necessary duration has also limited our understanding of the
natural history of EAC. Mathematical simulation models con-
structed by integrating the best available biologic, epidemiologic,
and clinical data can be useful in this circumstance [6]. Such
models improve our overall understanding of the natural history of
EAC, including the ability to estimate the unobservable transitions
between health states and can highlight areas to target for future
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furthermore provide the necessary foundation for cost-effective-
ness analyses which can inform clinical and policy decisions.
The aim of this article is to detail the construction of an EAC
model including: descriptions of model structure and inputs;
calibration endpoints and methodology; and model validation.
Additionally, for illustrative purposes, we provide a policy
application of the EAC model by retrospectively analyzing the
potential effects of a hypothetical national aspirin chemopreven-
tion program on EAC incidence. Epidemiologic analyses have
found that aspirin use is associated with a 50% decreased rate of
EAC [7]. We applied our natural history model as a systematic
method to estimate the lives saved under a hypothetical national
aspirin chemoprevention program. In the future, this validated
model can serve as the foundation for analyses that determine a
cost-effectiveness screening and management strategy for the
prevention of EAC morbidity and mortality.
Materials and Methods
Overview
The data sources for model development were from the
published literature and the National Cancer Institute’s Surveil-
lance, Epidemiology, and End Results (SEER) databases [2]. We
describe phases of the model development process: defining the
model structure or health states; specification of model parameters
and assumptions; and estimation of parameters by calibrating the
model to published studies and SEER data. Calibration is the
process of inferring the unknown transition probabilities in the
underlying biological processes by fitting the model output to the
empirical data (i.e. calibration targets). Model calibration can thus
identify a series of good-fitting parameters sets that are consistent
with the empirical data.
Model Structure
We developed a Markov state transition simulation model of
esophageal carcinogenesis with six health states including Normal,
GERD Symptoms, BE, Undetected Cancer, Detected Cancer and
Death as shown in Figure 1. Due to the complications of age-
dependent all-cause mortality and non-constant transition rates
between some health states, no exact analytical solution was found
for this model; hence we applied a simulation approach to solve for
the transition rates between the various pre-cancerous and
cancerous states. The model was programmed in Visual C++
using the Microsoft.NET Version 2.0 Framework (Redmond,
WA).
At the start of a simulation, a cohort of 20 year old white men
enters the model from the Normal health state. Individuals in a
health state can progress to the next state based on an annual
transition probability. At any point in the simulation, individuals
can die (and enter the absorbing Death state) from age-dependent
all-cause mortality in the pre-cancerous states. However, once
individuals develop cancer, they are subjected to cancer-specific
mortality rates. Since a significant percentage of patients with BE
report no GERD symptoms [8], the model also allows for
progression from the Normal health state directly to the BE health
state.
Model Assumptions
In accordance with the consensus reached during an NIH-
sponsored conference [R13 DK079674] regarding future disease
models of BE and EAC [9], we assumed there was no regression
among health states; although, regression from some of the health
states may be biologically plausible. Additionally, other health
states such as dysplasia (both low grade and high grade) were not
included. These assumptions allowed us to maintain a parsimo-
nious model, which simplified the model calibration process.
Although not depicted in our basic schematic, the BE state was
further sub-classified into Long Segment BE (LSBE) and Short
Segment BE (SSBE) by a ratio of 1:3 in agreement with the range
found in the literature [10,11,12]. We used a surface area rationale
that assumed the progression rates for SSBE was half of that for
LSBE, or at a 1:2 ratio because of the limited data in the existing
literature regarding cancer progression in SSBE [13]. We only
modeled white men as they account for the majority of the cases of
EAC in the U.S. [1]. See more details regarding this limitation and
others in the Discussion section. For the aspirin chemoprevention
analysis, the model only included the effects of progression rate
reduction by aspirin from BE to Undetected Cancer.
Parameterization
To aid in establishing the parameter boundaries in the model, a
comprehensive literature search was performed. Due to limited
publications in this area, only a few transition probabilities were
found in the published data; see Table 1.
Due to the lack of published data that provide GERD symptom
prevalence stratified by age, we started with an overall prevalence of
approximately 20% [14]; we then performed a weighted regression on
data from all available studies [3,12,15,16,17,18,19,20,21,22,23,24]
that presented the mean age and GERD symptoms prevalence of the
study group. The regression resulted in an overall prevalence of 18.6%
(weighted average), which is consistent with the US estimate by Locket
et al [14] which reported the GERD symptom prevalence in a range
between 17.7%–21.9% (95% confidence intervals). Further informa-
tion on this can be found in the Appendix S1.
Figure 1. Schematic of the Model Structure.
doi:10.1371/journal.pone.0009483.g001
Esophageal Cancer Model
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has a wide range (0.8–25%) [10,11,12,25,26,27,28,29,30,31]. The
evolving definition of BE with the inclusion of short-segment and
ultra-short segment BE has been one of the causes for this ambiguity.
The BE prevalences used as the calibration endpoints for our model
focused on three specific studies.
The two largest and methodologically most rigorous studies that
estimated population prevalences of BE were published by Rex et
al [11] and Ronkainen et al [12]. It has been hypothesized that
differing diagnostic criteria (e.g. endoscopic biopsy methods) could
have contributed to the divergent findings. Consequently, we
chose to average the results of these two similar sized studies and
estimated that the overall prevalence of BE in the US population
was approximately 4.2% in the base case. We then performed a
linear regression on the age-specific BE prevalences from the
Cameron article and recorded the resulting regression slope.
Further information on this can be found in the Appendix S1.
Since the ‘‘Undetected Cancer’’ state is by definition unobserv-
able, the transition rates to and from this state are associated with
a high level of uncertainty. However, some data on the sojourn time
of ‘‘Undetected Cancer’’ were found in the literature. For our
analysis, sojourn time was defined as the length of time it would take
for an undetected cancer to progress and to become detected due
to clinical symptoms such as dysphagia (difficulties swallowing) or
weight loss. A study estimated that the time from endoscopically
detectable EAC to clinical symptoms was on average 4–5 years
[32]. We reasoned that the Undetected Cancer state would likely
occur before the endoscopically detectable EAC used in the study.
Accordingly, to account for the earlier occurrence of Undetected
Cancer, the range was broadened to 4–9 years.
Calibration Targets
Calibration targets were derived using published data and
included age-specific prevalences of individuals in the U.S. with
GERD Symptoms and BE as well as age-specific U.S. incidences
of EAC based on SEER data [2]. See Table 2 for summary. Also
see the Appendix S1 for additional details regarding the methods
used for model calibration and validation.
We used SEER incidence data from calendar year 1973–2000
for model calibration; 2001–2005 data were reserved for
validation. The time span of 28 years used in calibration allowed
the model to capture the rapidly rising EAC incidence. In contrast,
we assumed that the other primary calibration targets of GERD
Symptom and BE prevalence were not subject to any secular
Table 1. Model Inputs: Selected Parameters Estimates.
Parameter Value Range References
Population Prevalence (%)
GERD Symptoms Prevalence 18.6 17.6–19.9 [3,12,15,17,18,19,20,21,22,23,24]
BE Prevalence 4.2 0.8–25 [10,11,12,25,26,27,28,29,31,43]
Transition Probabilities
Normal to GERD
Symptoms
Derived From
Calibration
Derived From
Calibration
Normal to BE 00
GERD to BE 00
BE to Undetected CA 00
Undetected CA to
Detected CA
4.5 years 4–9 years [32,38]
Chemoprevention
Aspirin Effect on EAC 50% Reduction [36]
This table describes the literature-derived initial ranges and values used as model input parameters. Population prevalences of GERD and BE are not themselves model
parameters, but they are used to derive values for transition or progression from the ‘‘Normal’’ state to the ‘‘GERD’’ and ‘‘BE’’ states, respectively.
Derivation of these prevalence values are described in the Appendix S1.
Abbreviations: GERD=gastroesophageal reflux disease; BE=Barrett’s esophagus.
doi:10.1371/journal.pone.0009483.t001
Table 2. Calibration Targets.
Age Group EAC Incidence BE Prevalence* GERD Symptom Prevalence**
20–29 yrs 0.0 1.7 17.6
30–39 yrs 0.3 2.5 18.0
40–49 yrs 0.6 3.3 18.4
50–59 yrs 3.3 4.1 18.8
60–69 yrs 7.4 5.0 19.1
70–79 yrs 9.3 5.8 19.5
All data is from 1986, a representative year, chosen because it is the midpoint of our time period.
*Overall BE prevalence for the population is 4.2%.
**Overall GERD Symptom Prevalence is 18.6%.
Abbreviations: EAC=Esophageal Adenocarcinoma; BE=Barrett’s esophagus; GERD=gastroesophageal reflux disease.
doi:10.1371/journal.pone.0009483.t002
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changes in population age distributions over time) and did not
change in the 28 year calibration period. The calibration targets
are further stratified into 10-year age groups between ages of 20
and 79.
Table 2 provides an illustrative representative year, as SEER
incidence changes with calendar year, and presents EAC incidence
and BE and GERD symptom prevalences by age group for the
calendar year of 1986.
Empirical Calibration
We used calibration to identify parameters sets of transition
probabilities to ensure that the model outputs were consistent with
the three targets of cancer incidence (age-specific SEER data from
1973–2000) and prevalences of two biologic predecessor health
states (age-specific BE and GERD symptom prevalence). The
parameter search process, described below, produced numerous
sets of distinct transition probabilities resulting in model outputs
that had a good ‘‘fit’’ to the calibration targets. The ranges of the
resulting transition probabilities represent parameter uncertainty.
GOF metric and assessment of fit. To assess the adequacy
of the model parameters derived from calibration, the Chi-
Squared Goodness of Fit (GOF) was used as the metric to
compare model output to the calibration targets for each
parameter set used (see Appendix S1 for more details). The best-
fitting parameter sets were defined as those with the lowest GOF
scores. The best 1% (out of 10
5) or 1,000 parameter sets were
selected and used for model validation and the aspirin analysis.
The best 1% of the parameter sets was chosen instead of the top
5% to handle noise in fitting the three endpoints while still leaving
enough parameter sets to perform analysis. Additionally, analysis
of these best 1,000 parameters sets allowed us to infer a likely range
of minimum and maximum values for each transition probability.
Systematic search algorithm. In order to systematically
search the parameter space for model calibration in a reproducible
manner, we used the Simulated Annealing (SA) algorithm, a
commonly used engineering optimization technique [33]. In
each calibration run, 10
5 search simulations were performed. At
the beginning of the parameter search, random parameter values
were selected within the allowable parameter range. The SA
algorithm searches for the global minimal GOF score and has
been shown to efficiently sample the parameter space of simulation
models with large number of parameters [33].
Secular trend function. A prominent increase in the U.S.
EAC incidence has been observed over the past few decades. In
order to account for this rapid change in incidence, our model
required an additional secular function for the model output to
reproduce SEER cancer incidence. The options for where to
incorporate a secular trend function into the model were limited
because we assumed a stable prevalence of BE from 1973–2000.
Additionally, because the stage distributions of detected cancers
from SEER data have remained relatively constant since 1973, we
assumed that the transition rate from Undetected Cancer to
Detected Cancer was also stable over this time period. Once the
BE prevalence (pre-cursor) and the transition from Undetected to
Detected CA were ‘‘fixed’’, only the transition probability from BE
to Undetected Cancer could accommodate an additional secular
factor for the model output to accurately reproduce SEER cancer
incidence. Other cancer models and analyses have described the
incorporation of similar functions in order to approximate clinical
data that exhibit a secular trend [34,35]. Using different secular
trend functions, the model was fit to the calibration targets over
the 28 year span using a three phase calibration procedure
described below. A linear function was ultimately chosen because
it provided the best fit to the SEER incidence and was also the
most simple. See Appendix S1 for additional details regarding both
the secular trend function and three phase calibration.
Three phase calibration. The calibration process utilized
threetargetendpoints:GERD symptomprevalence,BEprevalence,
and SEER cancer incidence. The calibration procedure needed to
address the substantial heterogeneity in regards to both the sample
size (e.g. SEER data based a significant percentage of the U.S.
population) and data quality of the three calibration targets. As a
result, we chose a three phase calibration process to sequentially fit
each calibration target. Since the sequence of calibration could
affect the process and outcome, the biologic progression or Forward
order (GERD SymptomsRBEREAC) and the Reverse order
(EACRBERGERD symptoms) were tested to assess the impact of
order and to determine which was superior.
For each phase of the calibration, 10
5 SA parameter search
simulations were performed (one calibration run). The better
parameters sets were those with the 10% lowest GOF scores. Next,
the transition probabilities in the model were constrained to a
range limited by the minimum and maximum values of the better
parameter sets. For the Forward order, this process was first
performed to calibrate to GERD Symptom prevalence, followed
by BE prevalence, and then with final calibration to EAC
incidence.
Validation. SEER data from 2001–2005 were reserved for
model validation. After the model was calibrated to the three
targets from 1973–2000, the best 1,000 parameter sets selected
from the calibration process were used in the model to project the
EAC incidence for the U.S. population from 2001 to 2005. Since
the number of years in these two periods (28 years in the
calibration years and 5 years in the validation set) were unequal,
the scores were divided by the number of years to produce an
adjusted GOF score.
Our criterion to confirm validation was if the average adjusted
GOF scores of the best 1,000 parameter sets for the validation
years was less than 150% (or not inferior by more than 50%) of the
value for the calibration years.
Aspirin Simulation: Illustrative Analysis of Model Output
Overview. The use of non-steroidal anti-inflammatory drugs
(NSAIDs), particularly aspirin, could potentially have a significant
impact on the incidences of EAC. We performed a simulation
experiment in a hypothetical scenario to explore the impact of
using aspirin as a chemoprevention for EAC, providing an
illustration of the model utilization in clinical and public health
impact. The model analysis assumed all men at age 40 in the U.S.
initiated aspirin in the 1960s (run-in period prior to 1973 when the
analysis formally begins) and continued treatment until death for
chemoprevention against EAC. The protective effects of aspirin
were incorporated into the model to compare the EAC cancer
incidence with aspirin against the original model outputs without
aspirin. Model simulations used the best 1,000 parameters sets as
determined in the prior calibration process.
Based on epidemiologic studies, aspirin has been associated with
approximately a 50% decrease in EAC prevalence [36]. To
incorporate these data into an effect on transition rates from BE to
undetected cancer, we assumed a constant effect and used a
hazard function to translate a 50% decreased cancer rate at the
end of a 5 year period into a 13% decreased rate in annual
transitions. 1,000 simulations were run using the best parameter
sets from years 1973–2005 and the predicted EAC incidence for
the white male population were estimated for each simulation;
these incidences were then averaged to produce a composite
estimate. Sensitivity analysis was performed by varying the efficacy
Esophageal Cancer Model
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from 30–70% tested.
Results
Model Fit to Calibration Targets
The model fits to our first two calibration targets, GERD
Symptom and BE prevalences are presented in Figure 2. GERD
Symptom prevalence was plotted as a function of specific age
group in the upper portion of the graph and BE prevalence was
shown in the lower portion. The fits for the GERD Symptom
prevalence and BE prevalence are good as model outputs are in
agreement with the observed data.
The model fit to the SEER cancer incidence, the third
calibration target, is presented in Figures 3 and 4. In Fig. 3, the
age-adjusted EAC incidence rates are plotted as a function of
calendar year for both the Model and SEER data; in Fig. 4, the
EAC incidence rates are stratified by specific age groups. All
model outputs between years 2001–2005 are for validation.
Age group 20–29 is not shown in Fig. 4 because of the limited
resolution in the y-axis; however, the fit was similar or better
compared to the other age groups displayed.
Validation Results
The adjusted GOF scores (adjusted for number of years in the
period) of the superior (top 1%) parameter sets were calculated for
the validation years (2001–2005) and compared to the adjusted
GOF scores from the calibration years (1973–2000). The adjusted
GOF value for the validation set met criterion and even exceeded
expectations as it was lower than the GOF value for the calibration
set with a value of 1.159 compared to 1.30, respectively,
confirming model validation.
Aspirin Chemoprevention Analysis
The effect of a national aspirin chemoprevention program (all
white men age 40 and older) starting in 1960 is presented as a
graph in Fig. 5. The top line shows the base case result and
represents the scenario of aspirin resulting in a 50% reduction in 5
year cumulative EAC incidence. A sensitivity analysis varied the
potential efficacy of aspirin from 30–70% with results graphed
alongside the base case 50% reduction for ease of comparison.
The number of prevented cancers per year was estimated by using
the top 1% of parameter sets and calculating an average value,
presented with the range of predicted values.
The overall results of the base case 50% reduction are
summarized in Table 3. Notably, the range serves as a qualitative
indicator of the level of uncertainty in the model prediction. The
number of cancers prevented increases with time, which corre-
sponds to the overall rising incidence of EAC during this period.
Discussion
The incidence of EAC in the western world has been rising at
an alarming rate. However, the clinical data regarding the EAC
natural history is limited. The lack of clear and reliable clinical
evidence significantly stymies the development of effective health
policy to manage this pernicious cancer. The creation of a
simulation model of the natural history of EAC synthesizes the
available clinical data creating a unified, coherent, and compre-
hensive picture or understanding of this disease. The construction
of the model has already identified areas, such as the secular trends
of age-specific GERD symptom and BE prevalences, where
clinical data that are crucial to our understanding of the natural
history of EAC are particularly lacking. Future analyses will
further highlight and identify these pivotal areas which should be
targeted for future research. Any new data that becomes available
can be incorporated into the model, thereby allowing it to remain
relevant in the future as an integration of the best available data at
any time. Finally, our model provides the foundation for future
cost-effectiveness analyses to evaluate targeted screening and
various management strategies for EAC, a pressing clinical and
policy issue as there is currently no accepted strategy.
Figure 2. Calibration Targets: GERD Symptoms and BE Prevalences by Age Groups.
doi:10.1371/journal.pone.0009483.g002
Esophageal Cancer Model
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a population-based natural history simulation model of EAC. The
model was validated as the model fit to validation data was even
better than the fit to the calibration target data, exceeding our
predefined criterion. We also present the results of an illustrative
and exploratory analysis of aspirin chemoprevention using the
model to estimate the number of cases of EAC which could have
been prevented in the U.S. if aspirin therapy was universally
adopted among white males.
Simulation modeling in health care decision analysis is in its
early stages. Currently there are no standards for model
development or calibration. However a growing consensus
espouses the need for a systematic and reproducible method for
model calibration [37]. Our EAC model’s development included a
Figure 3. Annual Esophageal Adenocarcinoma Incidence by Year (1973–2005): SEER data versus Model Output.
doi:10.1371/journal.pone.0009483.g003
Figure 4. Annual Esophageal Adenocarcinoma Incidence: SEER data versus Model Output by Age Group.
doi:10.1371/journal.pone.0009483.g004
Esophageal Cancer Model
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scores for quantitative evaluation. Our modeling approach will
allow for relatively easy incorporation of future research data into
the model, maintaining an up-to-date coherent picture of our
current knowledge of the disease’s natural history.
Prior mathematical models of BE have analyzed the cost-
effectiveness of screening and surveillance for BE, as well as
chemoprevention and other treatments in these patients
[7,38,39,40,41]. However, these prior models were single-cohort
patient or disease oriented models as opposed to a population
model; additionally, they did not fully incorporate SEER data. As
a consequence, these models are not suited to analyze national
trends in U.S. incidence or to make future projections, limiting
their ability to inform public health research and policy decisions.
Our natural history model only included white men because
both BE and EAC are most prevalent in white males [1] and the
available natural history data from the literature has predomi-
nantly focused on this group. A natural history model that
included women and other races would suffer from a dearth of
clinical and empiric data to perform calibration and validation,
creating a model with a high level of uncertainty, mainly useful for
exploratory or hypothesis generating analyses.
Although SEER data provided high quality data regarding EAC
incidence rates, the other calibration targets (age-specific GERD
symptom and BE prevalences) were based on less reliable data
from the literature. Specifically, in the absence of convincing data
for or against the stability of GERD symptom and BE prevalences
over the time period studied, they were assumed to be constant.
Our analysis of SEER data, not reported here, suggests that the
stage distribution of EAC’s has not appreciably changed over time,
implying that the transition rate between Undetected Cancer to
Detected Cancer has not changed as well. In order to reproduce
the trend of the rapidly rising incidence over the past few decades,
our model assumed an increase in the temporal change in the
transition rate from BE to Undetected Cancer. Since the
Undetected Cancer state is largely an unobservable state, our
assumption of constant BE prevalence needs to be verified by
future research studies. Epidemiologic data of most cancer
Figure 5. Annual Cancer Incidence with Aspirin Chemoprevention.
doi:10.1371/journal.pone.0009483.g005
Table 3. EAC Cases Prevented By Aspirin Over Time.
1975–1980 1981–1985 1986–1990 1991–1995 1996–2000 2001–2005
Original CAs Over 5 Years 2310 4987 8668 13045 17997 24071
CAs From 1975 Onward 2310 7297 15964 29009 47006 71077
Prevented CAs 235 (215–256) 528 (483–574) 904 (829–984) 1315(1205–1435) 1748(1601–1912) 2290(2097–2505)
% Percent Reduction 10.2 (9.3–11.1) 10.6 (9.7–11.5) 10.4 (9.6–11.4) 10.1 (9.2–11.0) 9.7 (8.9–10.6) 9.5 (8.7–10.4)
Prevented CAs From 1975 Onward 235 (215–256) 763 (699–830) 1667(1528–1814) 2982(2733–3249) 4730(4333–5167) 7020(6431–7665)
The upper section of the table displays the expected numbers of EAC cases without aspirin, the 1
st row is by 5 year period interval and the 2
nd row is a cumulative tally.
The lower section displays the prevented numbers of cancers for each 5 year period as absolute numbers (1
st row) and percentages (2
nd row)) and the 3
rd row is a
cumulative tally of cancers prevented by aspirin. The values in parentheses represent the range found using the superior (top 1%) parameter sets.
Abbreviat
doi:10.1371/journal.pone.0009483.t003
Esophageal Cancer Model
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Because the biologic mechanism of this phenomenon is not well
understood, we did not incorporate this effect into our model to
avoid over-fitting, or the potential to fit the model to random error
or noise.
As with all models, ours is a simplification of reality. More
complicated model structure could be made to increase the clinical
accuracy of our model. As an example, we did not include certain
clinically relevant health states in the natural history of EAC such
as dysplasia (low grade and high grade), as well as stages of cancer.
This was in large part due to our decision to incorporate only the
essential features for this analysis and to maintain model simplicity
for fast computational speed. Other clinical details of EAC will be
added to the model in the future versions.
For the illustrative analysis of a national aspirin program effect
on EAC incidence, neither the potential cardiac benefits nor the
potential harms such as gastrointestinal bleeding were incorporate
and complete patient adherence rates was assumed. The purpose
of this simple analysis was to provide a relevant and illustrative
example; a more detailed analysis would incorporate these and
other realities as well as quality of life factors and cost.
Consequently, we caution the use of these results to guide clinical
recommendations until more conclusive clinical evidence is
available.
One advantage of a simulation model is that as new information
becomes available (e.g. additional years of SEER data), the model
can be updated with relative ease. Aspirin Esomeprazole
Chemoprevention Trial (AspECT) is a large randomized con-
trolled trial studying the effects of aspirin and acid suppression
therapy on progression rates from BE to EAC [42]. The trial is
currently ongoing and will provide high quality trial data not only
regarding aspirin, but also about the natural history of BE (control
arm). An interim analysis is planned within the next few years and
this valuable data could also be incorporated into our model.
Future developments to the model could include: the addition of
clinically relevant health states such as dysplasia and cancer stage,
the incorporation of risk factors, and quality of life utilities and
cost. These additions to the model would permit us to conduct
effectiveness and cost-effectiveness analyses to evaluate various
screening and management strategies for EAC prevention.
Supporting Information
Appendix S1
Found at: doi:10.1371/journal.pone.0009483.s001 (0.18 MB
DOC)
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